Hormone Axis Discussion
Women's Hormonal Health Research Discussion
Educational protocol for female-specific HPG axis discussions and reproductive hormonal health research discussion points
• This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.
• All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.
• Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.
• Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.
High Risk — Specialist Supervision Required
Significant safety considerations; not suitable for unsupervised use
Overview
This educational protocol covers research discussion points for peptide compounds studied in women's hormonal health, including HPG axis regulation, hypothalamic amenorrhoea, female sexual health, and perimenopause-related research contexts. Given the complexity of female reproductive hormonal physiology, this protocol carries a HIGH RISK designation and requires specialist gynaecology or reproductive endocrinology oversight.
Mechanism Summary
Kisspeptin-10 is the active fragment of kisspeptin-54, acting through the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus to stimulate pulsatile GnRH release and downstream LH/FSH secretion. It is studied as a tool to restore HPG axis function in hypothalamic amenorrhoea. PT-141 (Bremelanotide) is a melanocortin receptor agonist (MC3R/MC4R) approved by the FDA for HSDD in premenopausal women; it acts centrally on hypothalamic pathways regulating sexual desire rather than through vascular mechanisms. Oxytocin research in perimenopause and female sexual health focuses on its role in social bonding, pain modulation, and potential hormonal interactions.
Intended Goal
Prepare for a clinician consultation on peptide compounds studied in women's HPG axis health, menopause-related research, and female reproductive hormonal health
Kisspeptin-10
HPG axis / GnRH stimulation / reproductive
Endogenous neuropeptide that activates GnRH pulse generation. Studied in hypothalamic amenorrhoea and reproductive endocrinology research. Catalog reference.
PT-141 (Bremelanotide)
Melanocortin / sexual function / HSDD
FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Prescription required. Catalog reference.
Oxytocin
Neuropeptide / reproductive / bonding / perimenopause research
Endogenous peptide studied in perimenopause, sexual wellness, and hormonal health contexts. Prescription required. Catalog reference.
Research reference values only. Confirm all parameters with current literature and your clinician.
Who may be a candidate
- ✓Women under gynaecology or reproductive endocrinology care discussing HPG axis health
- ✓Individuals with clinician-confirmed hypothalamic amenorrhoea exploring research options
- ✓Perimenopausal or menopausal women in consultation with a specialist
- ✓Those with clinician-confirmed HSDD discussing FDA-approved and research options
Exclusions
- ✕Not appropriate for use during active pregnancy or breastfeeding (unless specifically clinician-directed)
- ✕Not appropriate without specialist gynaecology or reproductive endocrinology oversight
- ✕Not appropriate for individuals seeking to self-manage hormonal conditions
Is Kisspeptin-10 appropriate for my type of amenorrhoea?
Am I a candidate for Bremelanotide (PT-141) for HSDD and what is the approved protocol?
How would you approach monitoring my HPG axis during a research compound program?
What is your clinical experience with peptide compounds in perimenopause?
How do you distinguish between hormonal and psychological contributions to my symptoms?
Print or copy these questions using the "Copy Summary" button to bring to your appointment.
Legal & Compliance Notice
PT-141 (Bremelanotide) is FDA-approved for HSDD and requires a prescription. Kisspeptin and oxytocin analogues are research compounds not approved for general therapeutic use. Verify all statuses with a specialist clinician.
The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.
This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.
Last reviewed: 2025-03-01 · Status: reviewed
Discuss with Your Clinician
Use this protocol as a research starting point. A qualified healthcare professional can review your health history, order appropriate labs, and help you determine what approach — if any — makes sense for your specific situation.